Market Overview:

The global vaccine market size reached US$ 49.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 88.8 Billion by 2028, exhibiting a growth rate (CAGR) of 10.3% during 2023-2028.

From a public health perspective, vaccines represent among the most important inventions in human history. A vaccine refers to a biological component that stimulates the production of antibodies against several pathogens present in the body. It is generally produced by using disease-causing agents and chemical drugs that act as antigens in disease prevention. Vaccines are primarily available in the form of conjugate vaccines, inactivated vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. They help in preventing various life-threatening diseases, including measles, polio, diphtheria, meningitis, influenza, tetanus, rotavirus, hepatitis, etc. As a result, vaccines are widely adopted for several immunization procedures, across hospitals, clinics, and vaccination centers, and for research purposes in academic and clinical laboratories.

The high prevalence of several infectious diseases is primarily driving the demand for vaccines. The growing consumer awareness towards effective immunization for eradicating various infections is further catalyzing the market growth. Moreover, the introduction of several vaccination programs by governments across various endemic regions is also propelling the demand for vaccines. Additionally, the market is also driven by the growing number of child deaths due to various infectious diseases, such as hepatitis, polio, measles, rubella, etc., particularly across the under-developed countries. The increasing involvement of several global organizations, such as the WHO, UNICEF, World Bank, Bill & Melinda Gates Foundation, etc. for developing adequate vaccination facilities in the endemic regions, is further catalyzing the product demand. Several pharmaceutical companies are focusing on the development of new and improved vaccines by accelerating the clinical trials of various pipeline drugs. Extensive R&D activities pertaining to the immunization of several fatal diseases, such as AIDS, Ebola, Hepatitis C, paratyphoid fever, etc., are also expected to fuel the market growth. The outbreak of the COVID-19 pandemic, leading to around half a million global deaths (as of June 2020), is currently creating opportunities for a novel vaccine against COVID-19.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global vaccine market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on technology, patient type, indication, route of administration, product type, treatment type, end user, and distribution channel.

Breakup by Technology:

• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Others
   

Breakup by Patient Type:

• Paediatric
• Adult
   

Breakup by Indication:

• Bacterial Diseases
  • Meningococcal Disease
  • Pneumococcal Disease
  • Diphtheria/Tetanus/Pertussis (DPT)
  • Tuberculosis
  • Haemophilus Influenzae (Hib)
  • Typhoid
  • Others
• Viral Diseases
  • Hepatitis
  • Influenza
  • Human Papillomavirus (HPV)
  • Measles/Mumps/Rubella (MMR)
  • Rotavirus
  • Herpes Zoster
  • Varicella
  • Japanese Encephalitis
  • Rubella
  • Polio
  • Rabies
  • Dengue
  • Others
     

Breakup by Route of Administration:

• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others
   

Breakup by Product Type:

• Multivalent Vaccine
• Monovalent Vaccine
   

Breakup by Treatment Type:

• Preventive Vaccine
• Therapeutic Vaccine
   

Breakup by End User:

• Hospitals
• Clinics
• Vaccination Centres
• Academic and Research Institutes
• Others
   

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Institutional Sales
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
  • Turkey
  • GCC Countries
  • Israel
  • Others
     

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, Bharat Biotech International, Bavarian Nordic A/S, CSL Limited, Daiichi Sankyo Company Limited, Emergent BioSolutions Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Johnson & Johnson, Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation), Novavax Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi Pasteur SA (Sanofi SA), Serum Institute of India Pvt. Ltd. and Takeda Pharmaceutical Company Limited.

Report Coverage: